• Recruiting

NCT04258683: Phase 2: Pembrolizumab Added to the Standard First-Line therapy (CyBorD) for NDMM NTE

Updated: Oct 12

NCT04258683: Phase 2: A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Canadian Myeloma Research Group

NCT04258683: Phase 2: A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE


This is a phase 2A multi-centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed patients with multiple myeloma that are not eligible for autologous stem cell transplantation.


Sponsor

Canadian Myeloma Research Group


Collaborator

Merck Sharp & Dohme LLC

 

ClinicalTrials.gov Identifier: NCT04258683

Official Title: A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added to The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib And Dexamethasone (CyBorD) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation

First Posted : February 6, 2020

Click here to see details on ClinicalTrials.gov

 

Drug: Pembrolizumab

 

Locations

Canada, Manitoba

Canada, New Brunswick

Canada, Quebec

Canada, Saskatchewan



Posts Archive